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ABSTRACT
Apoptosis is a tightly regulated, cell deletion process that plays an important role in various cardiovascular diseases, such as 
myocardial infarction, reperfusion injury, and heart failure. Since cardiomyocyte loss is the most important determinant of 
patient morbidity and mortality, fully understanding the regulatory mechanisms of apoptotic signaling is crucial. In fact, the 
inhibition of cardiac apoptosis holds promise as an effective therapeutic strategy for cardiovascular diseases. Caspase, a critical 
enzyme in the induction and execution of apoptosis, has been the main potential target for achieving anti-apoptotic therapy. 
Studies suggest, however, that a caspase-independent pathway may also play an important role in cardiac apoptosis, although 
the mechanism and potential significance of caspase-independent apoptosis in the heart remain poorly understood. Herein 
we discuss the role of apoptosis in various cardiovascular diseases, provide an update on current knowledge about the mo-
lecular mechanisms that govern apoptosis, and discuss the clinical implications of anti-apoptotic therapies. (Korean Circ J 
2010;40:299-305)
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Introduction
Heart disease is the leading cause of morbidity and mor-
tality in the developed world. Apoptosis, a highly regulated 
cell death process, plays an important role in numerous 
pathologic conditions involving the heart,
1)2) and the inhibi-
tion of apoptosis is emerging as a potential therapeutic strat-
egy. This review provides an overview of the evidence for 
apoptosis in cardiovascular disease, discusses the molecular 
pathways that may be involved, and reviews the clinical im-
plications.
Apoptosis in Cardiovascular Diseases
Apoptosis has been shown to be involved in both acute and 
chronic loss of cardiomyocytes in myocardial infarction, isc-
hemic heart disease, reperfusion injury, various forms of car-
diomyopathy, and the development of both acute and chronic 
heart failure.
3-5) Animal and human studies have demonstrat-
ed that apoptosis is present in the border zone of the infarct-
ed myocardium in the early phase, confirming the important 
role of apoptosis in acute myocardial loss after myocardial in-
farction.
6) 
Further studies showing that apoptosis is also present mon-
ths later suggest that apoptosis may also play a role in remod-
eling and in the subsequent development of heart failure.
7) 
Since cardiomyocyte loss is the most important determinant 
of morbidity and mortality after myocardial infarction, pre-
venting cardiomyocyte loss becomes a critical issue in the man-
agement of myocardial infarction. A better understanding of 
the regulatory mechanisms of apoptotic signaling is crucial in 
devising such strategies.
In contrast to acute myocardial injury, the pathogenesis of 
chronic heart failure is characterized by the progressive loss 
of cardiomyocytes evolving over months to years. Numerous 
studies involving human and animal models of heart failure 
suggest that apoptosis may be an important contributor to 
cardiomyocyte loss in the setting of heart failure.
3) However, 300   Apoptosis in Cardiovascular Diseases
since the prevalence of apoptosis is very low in most forms of 
chronic heart failure (usually <0.1% terminal deoxynucleo-
tidyl transferase dUTP nick end labeling-positive cells), whe-
ther or not apoptosis significantly contributes to the patho-
genesis of heart failure or is an epiphenomenon associated 
with end-stage heart failure is still debated.
5) Nevertheless, 
even at a very low level, the contribution of apoptosis over 
months to years is likely to prove clinically significant in pa-
tients with chronic heart failure. The current dilemmas are what 
forms of cell death (apoptotic vs. non-apoptotic) predomi-
nate in chronic heart disease, and whether or not the inhibi-
tion of cell death in the form of chronic inhibition therapy will 
prove beneficial in blocking the progression of clinical heart 
failure.
Mechanism of Apoptosis
Over the last two decades, much work has been done to id-
entify and elucidate the molecular mechanisms that regulate 
and execute apoptosis. These studies have shown that apop-
tosis is a tightly regulated, cell death process that involves close 
interactions among various pro- and anti-apoptotic molecules.   
It is generally agreed that apoptosis cannot be strictly identi-
fied by only one or two characteristics. In fact, a number of dif-
ferent types of mechanisms have been identified and charac-
terized, such as intrinsic vs. extrinsic pathway or caspase-de-
pendent vs. caspase-independent apoptosis. 
Caspase-mediated apoptosis
The caspases are a family of cysteine proteases that cleave 
target proteins at specific aspartate residues.
8)9) The caspases 
are produced as zymogens that are activated after cleavage of 
their prodomains.
8) Caspases are grouped based on structure 
and function. Initiator caspases possess a long prodomain 
with a functionally important interacting domain. Caspase-9 
and -8 are examples of initiator caspases, which act upstream 
to initiate and regulate apoptosis, and downstream to activate 
effector caspases. In comparison, effector caspases, such as 
caspase-3, are characterized by short prodomains, and gen-
erally depend on initiator caspases for activation. Studies show 
that homologous deletions of specific caspases most often 
cause tissue-specific or stimulus-dependent effects, rather than 
a global suppression of cell death.
10) These findings suggest 
that distinct sets of caspases may be involved in specific apop-
totic pathways, and they likely act in a tissue-specific manner. 
In general, caspase-mediated apoptosis occurs either by ex-
trinsic (involving death receptors) or intrinsic (mitochondria-
mediated) pathways (Fig. 1).
11-16) These two pathways usually 
converge on a common effector caspase, such as caspase-3, 
to execute the final morphologic and biochemical alterations 
Fig. 1. Schematic diagram of apoptotic signaling. Apoptosis can be initiated by caspase-dependent or -independent mechanisms. In caspase-
dependent mechanism, either death receptor or mitochondria (or both) are involved in initiation of apoptosis. In the caspase-independent me-
chanism, apoptotic factors, such as AIF, are released from the mitochondria, which trigger the apoptotic cascade. AIF: apoptosis inducing factor.Nam-Ho Kim, et al.   301
that are characteristic of apoptosis.
8) 
Extrinsic death receptor apoptotic pathway in cardiovascu-
lar disease 
The death receptor-mediated pathway is initiated by the 
binding of a death ligand {e.g., Fas ligand (FasL) or tumor 
necrosis factor-alpha (TNF-α)} to a membrane-bound death 
receptor (e.g., Fas or TNF-α receptor).
14) This interaction leads 
to the recruitment of a death domain {e.g., Fas-associated 
death domain (FADD)}, which activates caspase-8 followed 
by the downstream effector caspases. Several studies suggest 
that the extrinsic apoptotic pathway has an important patho-
physiologic role in the pathogenesis of heart failure.
17-23) The 
importance of FADD, for example, has been demonstrated 
by gene knockout, which causes embryonic lethality result-
ing from heart failure and abdominal hemorrhage.
17) Com-
ponents of the death receptor-mediated apoptotic pathway 
are up-regulated in cardiomyocytes during myocarditis, par-
ticularly in immune-mediated cardiomyopathy.
18) In human 
immunodeficiency virus cardiomyopathy, both death recep-
tor- and mitochondria-mediated apoptosis pathways are in-
volved in the apoptosis of cardiomyocytes.
19) In addition, sev-
eral studies have reported that failing human myocardium 
expresses high levels of TNF-α,
20)21) and transgenic mice over-
expressing cardiac-specific TNF-α develop dilated cardiomy-
opathy.
22)23) These data suggest that increased levels of TNF-α 
are detrimental to the heart by activation of the death receptor 
pathway.
The Fas pathway may be an important mediator of cardio-
myocyte apoptosis during ischemia/reperfusion (I/R) in vivo. 
Various knockouts of the death receptor pathway have been 
shown to improve cardiac function after I/R injury by inhib-
iting apoptosis. Mice lacking Fas exhibit reduction in infarct 
size after I/R.
24) However, the heart has high levels of death 
receptor pathway inhibitors, such as apoptosis repressor with 
caspase recruitment domain (ARC) and FLICE-inhibitory pro-
tein. Indeed, cardiac-specific overexpression of FasL does 
not cause increased cardiomyocyte apoptosis,
23)25) and TNF 
receptor 1 or 2 knockout in mice does not affect infarct size 
after coronary artery ligation.
26) These findings suggest that 
although the death receptor-mediated pathway could be im-
portant in certain situations (e.g., autoimmune-mediated he-
art failure), the role of the death receptor-mediated pathway 
in myocardial infarction or I/R is unclear. 
Intrinsic mitochondria-mediated apoptotic pathway in car-
diovascular diseases
Mitochondria constitute approximately 30% of the cell vol-
ume in cardiomyocytes, and play an essential role by generat-
ing adenosine triphosphate (ATP) for cellular function. How-
ever, upon apoptotic stimulation, such as oxidative stress and 
serum deprivation, mitochondria become a critical organelle 
in the initiation of cell death. In the mitochondria-mediated 
or intrinsic apoptotic pathway, an apoptotic insult induces the 
mitochondria to release cytochrome c into the cytosol.
11) Th-
ere mitochondria forms an activation complex, the apopto-
some, with apoptotic protein activating factor-1 (Apaf-1) and 
caspase-9.
12)27) Apoptosome formation results in the autopro-
cessing of caspase-9, as well as the activation of downstream 
caspases, such as caspase-3.
12)15) 
The regulation of the release of apoptotic factors, such as 
cytochrome c from mitochondria, is modulated by the Bcl-2 
family of proteins. The Bcl-2 family of proteins can be cate-
gorized as either anti-apoptotic (e.g., Bcl-2 and Bcl-xL) or 
pro-apoptotic (e.g., Bad, Bak, and Bax).
28)29) One of the pro-
apoptotic members, Bcl-2-interacting protein (Bid), may re-
gulate the interaction between death receptor and mitochon-
drial pathways. Bid is usually located in the cytosol, but when 
it is cleaved to ‘truncated Bid’ (tBid) by activated caspase-8, 
Bid translocates to the mitochondria and regulates cyto-
chrome c release.
30) The protective role of anti-apoptotic Bcl-2 
in the heart is demonstrated by the fact that cardiac-specific 
overexpression of Bcl-2 significantly reduces infarct size af-
ter I/R.
31)32) Deleting pro-apoptotic Bax also results in reduced 
infarct size and improved function after experimental myo-
cardial infarction.
33)
Additional regulatory mechanisms of caspase-mediated pa-
thways involve caspase inhibitors. Inhibitor of apoptosis pro-
teins (IAPs) are prototypical inhibitors of caspases that block 
caspase function, usually by directly binding to the caspas-
es.
34) Cardiac-specific overexpression of cIAP2 reduces in-
farct size after I/R in isolated perfused hearts.
35) Another im-
portant caspase inhibitor is ARC, which is found in high levels 
in skeletal muscle and heart.
36)37) ARC interacts with upstream 
caspases and has been shown to block caspase-2 and -8, as 
well as cytochrome c release. The overexpression of ARC de-
creases infarct size after I/R.
38) We have also identified other 
anti-apoptotic factors, such as HS-1 associated protein-1 (HAX-
1), which acts by directly interacting with pro-caspase-9, and 
prevents its activation.
39) 
Caspase-independent apoptosis (Fig. 1)
Although caspase activation is most likely the predominant 
mechanism in the induction of apoptosis, accumulating evi-
dence demonstrates that apoptosis may also be mediated by 
mechanisms that do not involve caspases.
40-42) The so-called 
caspase-independent pathways involve the release of apoptot-
ic factors, such as apoptosis inducing factor (AIF), from mi-
tochondria to the cytosol followed by translocation to the 
nucleus, where they cause deoxyribonucleic acid (DNA) frag-
mentation without concurrent caspase activation.
43)44) In con-
trast to caspase-mediated apoptosis, which is characterized by 
an oligonucleosomal DNA fragmentation in multiples of -200 
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independent apoptosis is characterized by large scale DNA fr-
agmentation (-50 kbp) with an early chromatin condensation 
pattern.
41)42) The potential importance of caspase-independent 
pathways in the heart is highlighted by the fact that cardio-
myocytes contain high levels of endogenous caspase inhibi-
tors, thereby making them relatively resistant to caspase-de-
pendent apoptosis.
40) Thus, the role of caspase-independent ap-
optosis may be amplified in the heart. 
Apoptosis-inducing factor
The best documented example of caspase-independent ap-
optosis involves AIF,
41-43)45)46) AIF is a flavoprotein localized 
in the mitochondrial intermembrane space and is required 
for oxidative phosphorylation.
47) Upon apoptotic stimulation, 
AIF is released into the cytosol and translocates into the nucle-
us to induce DNA fragmentation without caspase activation.
41) 
This notion is supported by the fact that microinjection of 
AIF into cells induces apoptotic changes, such as chromatin 
condensation, that are not blocked by a caspase inhibitor 
(zVAD.fmk),
41)48) In the heart, AIF has been implicated in 
apoptosis induced by oxidative stress, ischemia reperfusion, 
and heart failure in vitro and in vivo.
49)50) AIF also accumu-
lates in the cytosolic and nuclear fractions of the heart fol-
lowing I/R.
51) We have demonstrated significant activation 
of caspase-independent apoptosis in the Dahl salt-sensitive 
rat model of heart failure.
52) We have also recently shown that 
AIF-induced apoptosis is activated in cardiomyocytes, espe-
cially in hypertrophic cardiomyocytes.
53)  
Despite its pro-apoptotic function, AIF has also been shown 
to possess an essential pro-survival function. Homozygous 
AIF knockout in a mouse is lethal to embryos,
54) and the Har-
lequin (Hq) mouse, which expresses 10-20% of normal AIF 
levels, is prone to increased damage from I/R injury.
55) In ad-
dition, a mouse with cardiac and skeletal muscle-specific kn-
ockout of AIF develops severe dilated cardiomyopathy and 
skeletal atrophy accompanied by defective mitochondrial re-
spiratory activity.
56) How, then, is AIF able to function as both 
a survival and a death-inducing factor? An elegant study by 
Cheung et al.
57) using gene-targeted mice with various AIF mu-
tants demonstrated that AIF is required for cell survival and 
normal mitochondrial respiration in neurons. On the other 
hand, during apoptotic stimulation, the pro-apoptotic func-
tion of AIF is recognized when AIF is released from mitoch-
ondria and translocates to the nucleus, where it promotes DNA 
damage. 
Other factors involved in caspase-independent apoptosis
Other caspase-independent apoptotic effectors have been 
demonstrated, including endonuclease G (Endo G), serine 
protease high temperature requirement protein A2 (HtrA2/
Omi), and Bnip3. Endo G, a conserved nuclease, is involved 
in mitochondrial DNA replication with important roles in 
recombination and repair. Similar to AIF, Endo G translocates 
from the mitochondria to the nucleus during apoptosis and 
induces DNA fragmentation independent of caspases.
58-60) 
Endo G and truncated AIF become the essential mediators of 
apoptosis in a caspase-independent manner in cardiomyo-
cytes.
61) Interestingly, Endo G null mice, however, do not have 
any obvious defects in development or in the regulation of 
apoptosis.
58)59) HtrA2/Omi, a mitochondrial serine protease 
with pro-apoptotic properties, may also contribute to caspase-
independent apoptosis.
62) There is evidence that HtrA2/Omi 
also translocates from the mitochondria to the cytosol dur-
ing I/R to induce apoptosis. In heart, a specific HtrA2/Omi 
inhibitor, ucf-101, has also been shown to attenuate apopto-
sis and decrease infarct size.
63) 
Other types of cell death
Endoplasmic reticulum-stress death pathway
The endoplasmic reticulum (ER) is responsible for the syn-
thesis and folding of secreted proteins, as well as Ca
2+ storage. 
Several studies have demonstrated a role for ER stress in the 
pathogenesis of diabetes and heart failure.
64) Consistent with 
these observations, defective ER quality control in transgenic 
mice with mutant KDEL receptor (a receptor for ER chaper-
ones) causes dilated cardiomyopathy,
65) suggesting that apop-
tosis mediated by ER stress may be a significant contributor to 
cardiovascular disease. ER stress-induced cell death may oc-
cur via two different mechanisms. Under ER stress, activated 
caspase-12 activates caspase-3, leading to apoptosis.
66) The sec-
ond death-signaling pathway activated by ER stress is activa-
tion of a transcriptional program via up-regulation of the tran-
scription factor, CHOP/GADD 153. CHOP activates the tr-
anscription of genes encoding pro-apoptotic proteins, includ-
ing the BH3-only protein, Puma.
67) Recently, it has been sug-
gested that Puma is a critical component of ER stress-induced 
apoptosis in cardiac myocytes.
68) The Bcl-2 proteins have been 
shown to localize to the ER, where they can regulate the levels 
of Ca
2+ stored in the ER.
69)
Non-apoptotic cell death
This review is focused on apoptotic cell death, but non-ap-
optotic mechanisms, such as necrosis and autophagy, are 
also important cell death processes in heart. Necrosis, which 
has often been viewed as an accidental and uncontrolled cell 
death process, might also be a highly orchestrated type of pro-
grammed cell death, such as apoptosis, and this subset of reg-
ulated necrosis is termed necroptosis.
70) Unlike apoptosis or 
necrosis, autophagy is primarily involved in survival. Autoph-
agy enables cells to dispose of cytoplasm and organelles by 
fusing vesicles containing cellular components and lysoso-
mes.
71) However, several studies have demonstrated that au-
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sible association with the caspases and Bcl-2.
72-75) We also re-
cognize that there is considerable controversy at present ar-
ound differentiating the various types of cell death. There 
may be a spectrum of different mechanisms, and which mode 
of cell death predominates depends on the specific type of 
apoptotic stimuli, the degree of insult, and the intracellular 
ATP concentration. These are important and controversial is-
sues at this time, and further studies are needed to clarify these 
modes of cell death. 
Inhibition of Apoptosis as Therapy  
for Cardiovascular Disease
Since apoptosis is implicated in the pathogenesis of many 
different cardiovascular diseases, the inhibition of apoptosis 
promises to be an extraordinarily important target for thera-
peutic intervention. Even though the therapeutic targeting 
of apoptotic pathways has potential in the treatment of heart 
failure, several important questions remain to be answered. 
First, it has not been shown whether or not the inhibition of 
apoptosis can delay or prevent the development of heart fail-
ure. It is possible that inhibiting apoptosis may simply result 
in the activation of another mode of cell death, such as ne-
crosis, which may have more deleterious effects on neighbor-
ing cells and ultimately a worse outcome. Although the early 
studies on animal models of heart failure have been encour-
aging, the long-term consequences of inhibiting apoptosis in 
the heart are not known. Second, the safety of anti-apoptotic 
therapy has not been rigorously tested. Apoptosis is needed 
for the normal functioning of various cell systems, such as 
the immune system, and an excessive inhibition of apoptosis 
is associated with lymphoma or autoimmune disorders. Th-
erefore, the chronic systemic inhibition of apoptosis may have 
significant deleterious consequences in non-cardiac organs. 
Third, anti-apoptotic therapy for heart failure may not apply 
to all types of heart failure. The most ideal conditions for anti-
apoptotic intervention, in our opinion, occur in transient and 
acute insults, such as reperfusion. During reperfusion, cardio-
myocyte apoptosis occurs at a high rate during a defined time 
period; thus, a short treatment period may be highly effec-
tive. Moreover, a short therapeutic course has the additional 
benefit of minimizing the possible deleterious side effects aris-
ing in other organ systems.
Future Outlook and Conclusion
It is clear that apoptosis plays a critical role in the pathogen-
esis of various cardiovascular diseases and the inhibition of 
apoptosis promises to be an extraordinarily important target 
for therapeutic intervention. However, more work is neces-
sary to understand the molecular mechanisms that govern 
these processes, and the significance of apoptosis in heart fail-
ure. For example, although caspase inhibition has been shown 
to reduce the acute loss of myocardium in various animal mo-
dels,
76)77) caspase inhibition might not be completely effective 
in blocking apoptotic cell death.
78) With the potentially sig-
nificant contribution of caspase-independent apoptotic cell 
death in the heart, it is important to better define the role of 
the caspase-independent pathway in cardiac apoptosis at this 
time. Further work must be carried out in well-defined ex-
perimental frameworks that are tissue-targeted and time-spe-
cific, with clear quantitative end points. Only then will we be 
able to conduct meaningful human studies to answer the qu-
estion of whether the inhibition of apoptosis in heart failure 
will translate into clinical benefit.
Acknowledgments
This study was supported in part by grants from the National Institutes 
of Health RO1 HL091998 (P.M.K.), and the World Class University pro-
gram from the Korean National Research Foundation (P.M.K.).
REFERENCES
1)	Saraste A, Voipio-Pulkki LM, Parvinen M, Pulkki K. Apoptosis in the 
heart. N Engl J Med 1997;336:1025-6; discussion 6.
2)	Kang PM, Izumo S. Apoptosis in heart: basic mechanisms and impli-
cations in cardiovascular diseases. Trends Mol Med 2003;9:177-82.
3)	Kang PM, Izumo S. Apoptosis and heart failure: a critical review of the 
literature. Circ Res 2000;86:1107-13.
4)	Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reper-
fusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 
1994;94:1621-8.
5)	Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human he-
art. N Engl J Med 1997;336:1131-41.
6)	Olivetti G, Quaini F, Sala R, et al. Acute myocardial infarction in hu-
mans is associated with activation of programmed myocyte cell death 
in the surviving portion of the heart. J Mol Cell Cardiol 1996;28: 
2005-16.
7)	Takemura G, Ohno M, Hayakawa Y, et al. Role of apoptosis in the dis-
appearance of infiltrated and proliferated interstitial cells after myo-
cardial infarction. Circ Res 1998;82:1130-8.
8)	Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends 
Biochem Sci 1997;22:299-306.
9)	Pop C, Salvesen GS. Human caspases: activation, specificity, and reg-
ulation. J Biol Chem 2009;284:21777-81.
10)	Zheng TS, Hunot S, Kuida K, Flavell RA. Caspase knockouts: matters 
of life and death. Cell Death Differ 1999;6:1043-53.
11)	Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptot-
ic program in cell-free extracts: requirement for dATP and cytochrome 
c. Cell 1996;86:147-57.
12)	Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-depen-
dent formation of Apaf-1/caspase-9 complex initiates an apoptotic 
protease cascade. Cell 1997;91:479-89.
13)	Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human pro-
tein homologous to C. elegans CED-4, participates in cytochrome c-
dependent activation of caspase-3. Cell 1997;90:405-13.
14)	Nagata S. Apoptosis by death factor. Cell 1997;88:355-65.
15)	Slee EA, Harte MT, Kluck RM, et al. Ordering the cytochrome c-ini-
tiated caspase cascade: hierarchical activation of caspases-2, -3, -6, 
-7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 1999;144: 
281-92.
16)	Kang PM, Haunstetter A, Aoki H, Usheva A, Izumo S. Morphological 
and molecular characterization of adult cardiomyocyte apoptosis dur-
ing hypoxia and reoxygenation. Circ Res 2000;87:118-25.
17)	Yeh WC, Pompa JL, McCurrach ME, et al. FADD: essential for em-304   Apoptosis in Cardiovascular Diseases
bryo development and signaling from some, but not all, inducers of ap-
optosis. Science 1998;279:1954-8.
18)	Ishiyama S, Hiroe M, Nishikawa T, et al. The Fas/Fas ligand system is 
involved in the pathogenesis of autoimmune myocarditis in rats. J Im-
munol 1998;161:4695-701.
19)	Twu C, Liu NQ, Popik W, et al. Cardiomyocytes undergo apoptosis 
in human immunodeficiency virus cardiomyopathy through mitochon-
drion- and death receptor-controlled pathways. Proc Natl Acad Sci 
U S A 2002;99:14386-91.
20)	Doyama K, Fujiwara H, Fukumoto M, et al. Tumour necrosis factor 
is expressed in cardiac tissues of patients with heart failure. Int J Car-
diol 1996;54:217-25.
21)	Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha 
and tumor necrosis factor receptors in the failing human heart. Cir-
culation 1996;93:704-11.
22)	Bryant D, Becker L, Richardson J, et al. Cardiac failure in transgenic 
mice with myocardial expression of tumor necrosis factor-alpha. Cir-
culation 1998;97:1375-81.
23)	Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in 
transgenic mice with cardiac-specific overexpression of tumor necro-
sis factor-alpha. Circ Res 1997;81:627-35.
24)	Lee P, Sata M, Lefer DJ, Factor SM, Walsh K, Kitsis RN. Fas pathway 
is a critical mediator of cardiac myocyte death and MI during isch-
emia-reperfusion in vivo. Am J Physiol Heart Circ Physiol 2003;284: 
H456-63.
25)	Nelson DP, Setser E, Hall DG, et al. Proinflammatory consequences 
of transgenic fas ligand expression in the heart. J Clin Invest 2000; 
105:1199-208.
26)	Kurrelmeyer KM, Michael LH, Baumgarten G, et al. Endogenous 
tumor necrosis factor protects the adult cardiac myocyte against isch-
emic-induced apoptosis in a murine model of acute myocardial infarc-
tion. Proc Natl Acad Sci U S A 2000;97:5456-61.
27)	Bao Q, Shi Y. Apoptosome: a platform for the activation of initiator 
caspases. Cell Death Differ 2007;14:56-65.
28)	Youle RJ, Strasser A. The BCL-2 protein family: opposing activities 
that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59.
29)	Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. 
Science 1998;281:1322-6.
30)	Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates 
the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 
94:491-501.
31)	Brocheriou V, Hagege AA, Oubenaissa A, et al. Cardiac functional 
improvement by a human Bcl-2 transgene in a mouse model of isch-
emia/reperfusion injury. J Gene Med 2000;2:326-33.
32)	Chen Z, Chua CC, Ho YS, Hamdy RC, Chua BH. Overexpression of 
Bcl-2 attenuates apoptosis and protects against myocardial I/R injury 
in transgenic mice. Am J Physiol Heart Circ Physiol 2001;280:H2313- 
20.
33)	Hochhauser E, Cheporko Y, Yasovich N, et al. Bax deficiency reduces 
infarct size and improves long-term function after myocardial infarc-
tion. Cell Biochem Biophys 2007;47:11-20.
34)	Salvesen GS, Dixit VM. Caspase activation: the induced-proximity 
model. Proc Natl Acad Sci U S A 1999;96:10964-7.
35)	Sun CK, Chang LT, Sheu JJ, et al. Losartan preserves integrity of 
cardiac gap junctions and PGC-1 alpha gene expression and prevents 
cellular apoptosis in remote area of left ventricular myocardium fol-
lowing acute myocardial infarction. Int Heart J 2007;48:533-46.
36)	Ekhterae D, Lin Z, Lundberg MS, Crow MT, Brosius FC 3rd, Nunez 
G. ARC inhibits cytochrome c release from mitochondria and protects 
against hypoxia-induced apoptosis in heart-derived H9c2 cells. Circ 
Res 1999;85:e70-7.
37)	Koseki T, Inohara N, Chen S, Nunez G. ARC, an inhibitor of apopto-
sis expressed in skeletal muscle and heart that interacts selectively 
with caspases. Proc Natl Acad Sci U S A 1998;95:5156-60.
38)	Pyo JO, Nah J, Kim HJ, et al. Protection of cardiomyocytes from isch-
emic/hypoxic cell death via Drbp1 and pMe2GlyDH in cardio-specif-
ic ARC transgenic mice. J Biol Chem 2008;283:30707-14.
39)	Han Y, Chen YS, Liu Z, et al. Overexpression of HAX-1 protects car-
diac myocytes from apoptosis through caspase-9 inhibition. Circ Res 
2006;99:415-23.
40)	Bae S, Yalamarti B, Kang PM. Role of caspase-independent apopto-
sis in cardiovascular diseases. Front Biosci 2008;13:2495-503.
41)	Lorenzo HK, Susin SA, Penninger J, Kroemer G. Apoptosis inducing 
factor (AIF): a phylogenetically old, caspase-independent effector of 
cell death. Cell Death Differ 1999;6:516-24.
42)	Penninger JM, Kroemer G. Mitochondria, AIF and caspases: rivaling 
for cell death execution. Nat Cell Biol 2003;5:97-9.
43)	Cande C, Cecconi F, Dessen P, Kroemer G. Apoptosis-inducing fac-
tor (AIF): key to the conserved caspase-independent pathways of cell 
death? J Cell Sci 2002;115:4727-34.
44)	Cregan SP, Dawson VL, Slack RS. Role of AIF in caspase-dependent 
and caspase-independent cell death. Oncogene 2004;23:2785-96.
45)	Cregan SP, Fortin A, MacLaurin JG, et al. Apoptosis-inducing factor is 
involved in the regulation of caspase-independent neuronal cell death. 
J Cell Biol 2002;158:507-17.
46)	Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization 
of mitochondrial apoptosis-inducing factor. Nature 1999;397:441-6.
47)	Vahsen N, Cande C, Briere JJ, et al. AIF deficiency compromises oxi-
dative phosphorylation. EMBO J 2004;23:4679-89.
48)	Sharp TV, Wang HW, Koumi A, et al. K15 protein of Kaposi’s sarco-
ma-associated herpesvirus is latently expressed and binds to HAX-1, 
a protein with antiapoptotic function. J Virol 2002;76:802-16.
49)	Chen M, Zsengeller Z, Xiao CY, Szabo C. Mitochondrial-to-nuclear 
translocation of apoptosis-inducing factor in cardiac myocytes dur-
ing oxidant stress: potential role of poly (ADP-ribose) polymerase-1. 
Cardiovasc Res 2004;63:682-8.
50)	Xiao CY, Chen M, Zsengeller Z, et al. Poly (ADP-Ribose) polymerase 
promotes cardiac remodeling, contractile failure, and translocation 
of apoptosis-inducing factor in a murine experimental model of aortic 
banding and heart failure. J Pharmacol Exp Ther 2005;312:891-8.
51)	Kim GT, Chun YS, Park JW, Kim MS. Role of apoptosis-inducing 
factor in myocardial cell death by ischemia-reperfusion. Biochem Bio-
phys Res Commun 2003;309:619-24.
52)	Siu PM, Bae S, Bodyak N, Rigor DL, Kang PM. Response of caspase-
independent apoptotic factors to high salt diet-induced heart failure. 
J Mol Cell Cardiol 2007;42:678-86.
53)	Choudhury S, Bae S, Kumar SR, et al. Role of AIF in cardiac apopto-
sis in hypertrophic cardiomyocytes from Dahl salt-sensitive rats. Car-
diovasc Res 2010;85:28-37.
54)	Joza N, Susin SA, Daugas E, et al. Essential role of the mitochondrial 
apoptosis-inducing factor in programmed cell death. Nature 2001; 
410:549-54.
55)	van Empel VP, Bertrand AT, van der Nagel R, et al. Downregulation 
of apoptosis-inducing factor in harlequin mutant mice sensitizes the 
myocardium to oxidative stress-related cell death and pressure over-
load-induced decompensation. Circ Res 2005;96:e92-101.
56)	Joza N, Oudit GY, Brown D, et al. Muscle-specific loss of apoptosis-
inducing factor leads to mitochondrial dysfunction, skeletal muscle at-
rophy, and dilated cardiomyopathy. Mol Cell Biol 2005;25:10261-72.
57)	Cheung EC, Joza N, Steenaart NA, et al. Dissociating the dual roles of 
apoptosis-inducing factor in maintaining mitochondrial structure and 
apoptosis. EMBO J 2006;25:4061-73.
58)	David KK, Sasaki M, Yu SW, Dawson TM, Dawson VL. EndoG is 
dispensable in embryogenesis and apoptosis. Cell Death Differ 2006; 
13:1147-55.
59)	Irvine RA, Adachi N, Shibata DK, et al. Generation and characteriza-
tion of endonuclease G null mice. Mol Cell Biol 2005;25:294-302.
60)	Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when 
released from mitochondria. Nature 2001;412:95-9.
61)	Bahi N, Zhang J, Llovera M, Ballester M, Comella JX, Sanchis D. 
Switch from caspase-dependent to caspase-independent death during 
heart development: essential role of endonuclease in ischemia-induced 
DNA processing on differentiated cardiomyocytes. J Biol Chem 2006; 
281:22943-52.Nam-Ho Kim, et al.   305
62)	Suzuki Y, Takahashi-Niki K, Akagi T, Hashikawa T, Takahashi R. Mi-
tochondrial protease Omi/HtrA2 enhances caspase activation through 
multiple pathways. Cell Death Differ 2004;11:208-16.
63)	Liu HR, Gao E, Hu A, et al. Role of Omi/HtrA2 in apoptotic cell death 
after myocardial ischemia and reperfusion. Circulation 2005;111:90-6.
64)	Li Z, Zhang T, Dai H, et al. Involvement of endoplasmic reticulum st-
ress in myocardial apoptosis of streptozocin-induced diabetic rats. J 
Clin Biochem Nutr 2007;41:58-67.
65)	Hamada H, Suzuki M, Yuasa S, et al. Dilated cardiomyopathy caused 
by aberrant endoplasmic reticulum quality control in mutant KDEL 
receptor transgenic mice. Mol Cell Biol 2004;24:8007-17.
66)	Szegezdi E, Logue SE, Gorman AM, Samali A. Mediators of endo-
plasmic reticulum stress-induced apoptosis. EMBO Rep 2006;7:880-5.
67)	Li J, Lee B, Lee AS. Endoplasmic reticulum stress-induced apoptosis: 
multiple pathways and activation of p53-up-regulated modulator of 
apoptosis (PUMA) and NOXA by p53. J Biol Chem 2006;281:7260-70.
68)	Nickson P, Toth A, Erhardt P. PUMA is critical for neonatal cardio-
myocyte apoptosis induced by endoplasmic reticulum stress. Cardio-
vasc Res 2007;73:48-56.
69)	Scorrano L, Oakes SA, Opferman JT, et al. BAX and BAK regulation 
of endoplasmic reticulum Ca2+: a control point for apoptosis. Science 
2003;300:135-9.
70)	Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapop-
totic cell death with therapeutic potential for ischemic brain injury. 
Nat Chem Biol 2005;1:112-9.
71)	Kim J, Klionsky DJ. Autophagy, cytoplasm-to-vacuole targeting path-
way, and pexophagy in yeast and mammalian cells. Annu Rev Biochem 
2000;69:303-42.
72)	Gorski SM, Chittaranjan S, Pleasance ED, et al. A SAGE approach to 
discovery of genes involved in autophagic cell death. Curr Biol 2003; 
13:358-63.
73)	Lee CY, Baehrecke EH. Steroid regulation of autophagic programmed 
cell death during development. Development 2001;128:1443-55.
74)	Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and 
inhibition of tumorigenesis by beclin 1. Nature 1999;402:672-6.
75)	Berry DL, Baehrecke EH. Growth arrest and autophagy are required 
for salivary gland cell degradation in Drosophila. Cell 2007;131: 
1137-48.
76)	Laugwitz KL, Moretti A, Weig HJ, et al. Blocking caspase-activated 
apoptosis improves contractility in failing myocardium. Hum Gene 
Ther 2001;12:2051-63.
77)	Yaoita H, Ogawa K, Maehara K, Maruyama Y. Attenuation of isch-
emia/reperfusion injury in rats by a caspase inhibitor. Circulation 
1998;97:276-81.
78)	Okamura T, Miura T, Takemura G, et al. Effect of caspase inhibitors 
on myocardial infarct size and myocyte DNA fragmentation in the isch-
emia-reperfused rat heart. Cardiovasc Res 2000;45:642-50.